Tata India Pharma & Healthcare Fund Direct Growth
Equity
Direct
Sector - Healthcare
NAV as on 22-11-2024
₹ 34.34
▲0.1%
1D
Inception Returns
14.7%
/yr
About Tata India Pharma & Healthcare Fund Direct Growth
Tata India Pharma & Healthcare Fund Direct Growth is an equity fund. This fund was started on 28 December, 2015. The fund is managed by Meeta Shetty. The fund could potentially beat inflation in the long-run.
Key Parameters
- Tata India Pharma & Healthcare Fund Direct Growth has ₹1208 Cr worth of assets under management (AUM) as on Oct 2024 and is less than category average.
- The fund has an expense ratio 0.7.
Returns
Tata India Pharma & Healthcare Fund Direct Growth has given a CAGR return of 14.72% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 39.67%, 21.07% and 28.06% respectively.
Holdings
Tata India Pharma & Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Aurobindo Pharma Ltd, Lupin Ltd, Dr Reddy's Laboratories Ltd, Cipla Ltd
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 15%For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefitDividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.
Investment objective of Tata India Pharma & Healthcare Fund Direct Growth
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 100.00. Tata India Pharma & Healthcare Fund Direct Growth has no lock in period.
Historical NAV & Returns
Annualised
▲
▼
2715 people have invested ₹ 1.5Cr in Tata India Pharma & Healthcare Fund Direct Growth in the last three months
INDmoney Rank for Tata India Pharma & Healthcare Fund Direct Growth
Powered by IND quant engine
IND ranking is not available for this fund.
Beats FD returns for both 3Y & 5Y duration
5Y returns in the bottom 25% of the category
Tata India Pharma & Healthcare Fund Direct Growth Overview
| Expense ratio | 0.69% |
Benchmark | S&P BSE Healthcare PR |
| AUM | ₹1208 Cr |
| Inception Date | 28 December, 2015 |
| Min Lumpsum/SIP | ₹5000/₹100 |
Exit Load | 0.2% |
| Lock In | No Lock-in |
TurnOver | 28.44% |
| STCG | Redeeming before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
Trailing Returns
as on (22-Nov-24)
Fund Distribution
as on (31-Oct-24)
Large cap
40.3%
Mid cap
30.8%
Small cap
21.4%
Sector Allocation
Health
97.8%
Basic Materials
2.2%
All changes are between Aug'24 and Oct'24
- This fund’s returns stands at -1.32% whereas the fund’s underlying benchmark Nifty 500 returns stands at -6.52% as on Oct'24
- This fund outperformed Nifty 500 by 5.19% in Oct'24
- AUM of the fund stands at 1.2K Cr as of Oct'24
- AUM decreased by 0.2 Cr between Oct'24 and Sep'24
Top Stocks bought last month
Indoco Remedies Ltd's allocation increased from 1.09% to 1.71%
Divi's Laboratories Ltd's allocation increased from 4.73% to 5.12%
Wockhardt Ltd's allocation increased from 1.57% to 1.93%
Top Stocks sold last month
Sun Pharmaceuticals Industries Ltd's allocation decreased from 12.83 % to 12.31 %
Aurobindo Pharma Ltd's allocation decreased from 8.96 % to 8.57 %
Lupin Ltd's allocation decreased from 7.44 % to 7.43 %
Mid Cap allocation has gone down from 31.4% to 30.8%
Large Cap allocation has gone down from 41.7% to 40.3%
Small Cap allocation has gone up from 18.8% to 21.4%
Cash allocation has gone down from 6.3% to 5.4%
Top 2 Sectors in October were Health, Basic Materials
Oct'24
Health
98%
Basic Materials
2%
Sep'24
Health
98%
Basic Materials
2%
See all
Top Growth Drivers | 1M Return |
|---|---|
 Wockhardt Ltd | 11.1% |
 Piramal Pharma Ltd | 9.9% |
Loading...
We are taking more time than usual
Meeta Shetty
Fund Manager of Tata India Pharma & Healthcare Fund Direct Growth, since 9 March 2021
Top funds managed
Fund House
Tata Asset Management Limited
Total Schemes
Total AUM
₹1.87L Cr
as on 31-Oct-2024
Address
Tata Asset Management Private Limited,Mafatlal Centre, 9th Floor,,Nariman Point,,India
Phone
+912266578282
Website
kiran@tataamc.com
Mutual Fund Insights
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 0.69% which is lower than the category average expense ratio of 1.39%.
Over the last 6 months, this fund has decreased expense ratio by 17.9% moving from 0.84 to 0.69.
In the last 3 years, SBI Healthcare Opportunities Fund Direct Growth has given 24.5% return, outperforming this fund by 3.43% per annum.
In the last 5 years, DSP Healthcare Fund Direct Growth has given 32.43% return, outperforming this fund by 4.37% per annum.
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 51.62% return, outperforming this fund by 11.95%.
Over the last 6 months, this fund has experienced a 35.2% growth in AUM moving from 893.64 Cr to 1.20K Cr.
Tata India Pharma & Healthcare Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 14.72% since inception which is less than its category average return of 24.93%
Fund Allocations
This fund has an allocation of 94.62% in Equity, 0% in Debt and 5.38% in Cash related instruments
AUM size ₹1208 Cr
This fund has AUM of ₹1208 Cr which is less than its category average of ₹ 2001 Cr
Expense Ratio 0.69%
This fund has an expense ratio of 0.69% which is less than its category average expense ratio of 1.33%
Frequently Asked Questions for Tata India Pharma & Healthcare Fund Direct Growth
The current NAV of Tata India Pharma & Healthcare Fund Direct Growth is ₹34.34 as on 22-Nov-2024.
Existing (Absolute + CAGR) as on 22-Nov-2024.
Tata India Pharma & Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | -4.21% | -4.21% |
6 Month Returns | 15.26% | 15.26% |
1 Year Returns | 39.67% | 39.67% |
3 Years Returns | 77.44% | 21.07% |
5 Years Returns | 244.37% | 28.06% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
0.69% as on October 2024
₹1208 Cr as on October 2024
Sun Pharmaceuticals Industries Ltd(12.31%), Aurobindo Pharma Ltd(8.57%), Lupin Ltd(7.43%), Dr Reddy's Laboratories Ltd(6.48%), Cipla Ltd(6.29%) as on October 2024
The alpha ratio for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
Tata India Pharma & Healthcare Fund Direct Growth | 4.22 | 4.8 | 7.24 |
As on October 2024
The alpha for Tata India Pharma & Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
Tata India Pharma & Healthcare Fund Direct Growth | 0.95 | 0.91 | 0.8 |
As on October 2024
The Beta for Tata India Pharma & Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
Tata India Pharma & Healthcare Fund Direct Growth | 2.8 | 1.09 | 1.28 |
As on October 2024
The sharpe ratio for Tata India Pharma & Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
Tata India Pharma & Healthcare Fund Direct Growth | 14.86 | 15.09 | 17.41 |
As on October 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 2.21 as on October 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 1.22 as on October 2024. It tells the consistency of the fund in generating superior risk-adjusted performance
Meeta Shetty is the fund manager of Tata India Pharma & Healthcare Fund Direct Growth
The Exit load of Tata India Pharma & Healthcare Fund Direct Growth is 0.25%